Literature DB >> 17467176

Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation.

M J Day1.   

Abstract

Infection with Leishmania may have different outcomes in genetically distinct individuals and the course of infection is determined by the nature of the host innate and adaptive immune response. Thus in experimentally infected mice, and in naturally infected dogs or humans, the protective (self-healing or asymptomatic) phenotype is associated with the induction of Th1-regulated cell-mediated immunity. By contrast, a Th2-regulated humoral immune response is associated with severe symptomatic disease. In the murine model system there is strong correlation between clinicopathological phenotype and the nature of the antigen-specific humoral immune response. Symptomatic infection and Th2-regulation is associated with elevation in antigen-specific IgG1 and IgE, whereas asymptomatic infection with Th1-regulation is linked with IgG2a production. IgG subclass restriction is less clear in human disease with only some clinical forms being correlated to a specific serological profile. Although numerous studies have questioned whether infected dogs develop skewed IgG subclass usage, the results of these have been conflicting-suggesting bias towards IgG1 or IgG2 or neither subclass in different investigations. This confusion could relate to the specificity of the commercially available polyclonal antisera used to detect the canine IgG1 and IgG2 subclasses. More meaningful results might be obtained by the use of the panel of monoclonal antibodies with well-validated specificity for all four canine IgG subclasses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467176     DOI: 10.1016/j.vetpar.2007.03.037

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  24 in total

1.  Application of an improved enzyme-linked immunosorbent assay method for serological diagnosis of canine leishmaniasis.

Authors:  Nuno Santarém; Ricardo Silvestre; Luís Cardoso; Henk Schallig; Steven G Reed; Anabela Cordeiro-da-Silva
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

2.  Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice.

Authors:  Mohammad Ali Danesh-Bahreini; Javad Shokri; Afshin Samiei; Eskandar Kamali-Sarvestani; Mohammad Barzegar-Jalali; Soliman Mohammadi-Samani
Journal:  Int J Nanomedicine       Date:  2011-04-20

3.  A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Authors:  Erin E Thacker; Masaharu Nakayama; Bruce F Smith; R Curtis Bird; Zhanat Muminova; Theresa V Strong; Laura Timares; Nikolay Korokhov; Ann Marie O'Neill; Tanja D de Gruijl; Joel N Glasgow; Kenzaburo Tani; David T Curiel
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

Review 4.  The immunopathology of canine vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

5.  Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs.

Authors:  Javier Moreno; Ioannis Vouldoukis; Virginie Martin; David McGahie; Anne-Marie Cuisinier; Sylvie Gueguen
Journal:  PLoS Negl Trop Dis       Date:  2012-06-19

6.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

7.  Emergent canine visceral leishmaniasis in Argentina: Comparative diagnostics and relevance to proliferation of human disease.

Authors:  Kyoko Fujisawa; Charlotte Silcott-Niles; Poppy Simonson; Daniela Lamattina; Cristian A Humeres; Tapan Bhattacharyya; Pascal Mertens; Caroline Thunissen; Victoria O'Rourke; Magdalena Pańczuk; James A Whitworth; Oscar Daniel Salomón; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2021-07-19

8.  Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors.

Authors:  Dirlei Nico; Daniel Ferreira Feijó; Naiara Maran; Alexandre Morrot; Julio Scharfstein; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Parasit Vectors       Date:  2012-11-14       Impact factor: 3.876

9.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

10.  A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Authors:  Connor Carson; Maria Antoniou; Maria Begoña Ruiz-Argüello; Antonio Alcami; Vasiliki Christodoulou; Ippokratis Messaritakis; Jenefer M Blackwell; Orin Courtenay
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.